Symtuza(cobicistat / darunavir / emtricitabine / tenofovir alafenamide)
Symtuza 800 MG / 150 MG / 200 MG / 10 MG Oral Tablet

Dosage & Administration

Dosage & Administration

Testing: Prior to or when initiating SYMTUZA, test patients for HBV infection.

Prior to or when initiating SYMTUZA, and during treatment with SYMTUZA, on a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus. ( 2.1)

Recommended dosage: One tablet taken once daily with food in adults and pediatric patients, weighing at least 40 kg. ( 2.2)

Renal Impairment:SYMTUZA is not recommended in patients with estimated creatinine clearance below 30 mL/min. ( 2.3)

Hepatic Impairment: SYMTUZA is not recommended in patients with severe hepatic impairment. ( 2.4)

drug label

Symtuza Prescribing Information

samples

Request Symtuza Samples

Online Sample Form
Learn More

prior authorization

Symtuza Prior Authorization Resources

Most recent state uniform prior authorization forms

Verified: Jul 26, 2024Arizona - Uniform Prior Authorization Form
Verified: Jul 26, 2024Colorado - Uniform Prior Authorization Form
Verified: Jul 26, 2024Hawaii - Uniform Prior Authorization Form
Verified: Jul 26, 2024Illinois - Uniform Prior Authorization Form
Verified: Jul 26, 2024Indiana - Uniform Prior Authorization Form
Verified: Jul 26, 2024Louisiana - Uniform Prior Authorization Form
Verified: Jul 26, 2024Minnesota - Uniform Prior Authorization Form
Verified: Jul 26, 2024New Hampshire - Uniform Prior Authorization Form
Verified: Jul 26, 2024New Mexico - Uniform Prior Authorization Form
Verified: Jul 26, 2024Oregon - Uniform Prior Authorization Form
Verified: Jul 26, 2024Texas - Uniform Prior Authorization Form
Verified: Jul 07, 2024Washington - Uniform Prior Authorization Form
Verified: Jul 07, 2024Wisconsin - Uniform Prior Authorization Form
Complete Letter of Medical Necessity
Appeals Considerations Checklist
Appeals Considerations Checklist - Spanish
Formulary Exception Request Letter
Formulary Exception Request Letter - Spanish
PA Checklist

Benefits investigation

Benefits Investigation Form
Janssen Patient Support Program Patient Authorization Form

financial assistance

Symtuza Financial Assistance Options

Copay savings program

Enroll in Patient Savings Program
Learn More

Foundation programs

J & J Patient Assistance Foundation Eligibility Check
Learn More

patient education

Symtuza Patient Education

To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link

Patient toolkit

About Symtuza
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Stories
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Doctor Discussion Guide: Newly Diagnosed
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Doctor Discussion Guide: Patients Switching
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure: Newly Diagnosed
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure: Patients Switching
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

people also ask

Symtuza FAQs

How is the dosage of Symtuza?Symtuza is available in 1 dosages, including 150-800-200-10 mg Tab
What does Symtuza treat?Symtuza treats Acquired Immunodeficiency Syndrome, HIV Infections and Chronic Hepatitis B
What is Symtuza made of?Symtuza contains cobicistat / darunavir / emtricitabine / tenofovir alafenamide which is a Cytochrome P450 3A Inhibitor
How Is Symtuza Administered?Symtuza is administered as a Oral Pill
What Are The Symtuza Mechanism Of Action?Symtuza mechanism of action is Breast Cancer Resistance Protein Inhibitors, Cytochrome P450 2D6 Inhibitors, Cytochrome P450 3A Inhibitors, HIV Protease Inhibitors, Multidrug and Toxin Extrusion Transporter 1 Inhibitors, Nucleoside Reverse Transcriptase Inhibitors, Organic Anion Transporting Polypeptide 1B1 Inhibitors, Organic Anion Transporting Polypeptide 1B3 Inhibitors or P-Glycoprotein Inhibitors
FAQ Data Source